PMSNF (Proteome Sciences) Additional Paid-In Capital: $68.75 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Proteome Sciences Additional Paid-In Capital?

Proteome Sciences PMSNF Additional Paid-In Capital is $68.75 Mil as of Jun. 2026. The stock has 6 warning signs investors should review.


Proteome Sciences's quarterly additional paid-in capital increased from Dec. 2024 ($64.46 Mil) to Jun. 2025 ($70.53 Mil) but then stayed the same from Jun. 2025 ($70.53 Mil) to Jun. 2026 ($68.75 Mil).

Proteome Sciences's annual additional paid-in capital declined from Dec. 2023 ($65.61 Mil) to Dec. 2024 ($64.46 Mil) but then increased from Dec. 2024 ($64.46 Mil) to Dec. 2025 ($69.22 Mil).

Proteome Sciences Additional Paid-In Capital Related Terms

Proteome Sciences Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Additional Paid-In Capital Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.71 61.91 65.61 64.46 69.22

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.61 65.06 64.46 70.53 68.75

Proteome Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $68.75 Mil mean?
Proteome Sciences (PMSNF) has a Additional Paid-In Capital of $68.75 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Proteome Sciences and its competitors.
Is Proteome Sciences' Additional Paid-In Capital too high?
Proteome Sciences' current Additional Paid-In Capital is $68.75 Mil.
How does Proteome Sciences' Additional Paid-In Capital compare to TMO and DHR?
Proteome Sciences' Additional Paid-In Capital of $68.75 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Diagnostics & Research company?
A good Additional Paid-In Capital depends on the Medical Diagnostics & Research industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Additional Paid-In Capital is $68.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (PMSNF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.01 — trading 62.7% below its estimated fair value. The current Additional Paid-In Capital is $68.75 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current Additional Paid-In Capital is $68.75 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRMl:UKPRM:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.